There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Centessa Pharmaceuticals (CNTA – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments.
Centessa Pharmaceuticals (CNTA)
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Centessa Pharmaceuticals yesterday and set a price target of $15.00. The company’s shares closed last Friday at $6.70.
According to TipRanks.com, Biliouris is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Centessa Pharmaceuticals with a $11.33 average price target, representing an 87.3% upside. In a report issued on November 29, Leerink Partners also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $425.00. The company’s shares closed last Friday at $351.16.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $390.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CNTA:
- Centessa’s (NASDAQ:CNTA) Narcolepsy Drug Wakes Up Investors
- Centessa upgraded to Buy from Hold at Jefferies
- Centessa reports Q3 EPS (40c), consensus (52c)
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
- CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
